Clearmind is the only one working with MEAI.

Clearmind owns the IP for MEAI covering its use as a binge mitigator & as alcohol substitute in many jurisdictions.

Alcohol Use Disorder is in an ongoing epidemic with 100s of millions affected.

Excessive alcohol consumption costs $249B/year to the US market, higher than that of depression, diabetes or heart disease.

One of the most substantial unfulfilled medical and societal needs

Management has previously brought 2 drugs to the market.1

Experienced in regulatory processes with FDA and Health Canada.

Management team has expertise in pharma, finance, strategy and psychedelics.

MEAI is expected to give immediate results, be self-administered as a prescription pill, and non-addictive.

MEAI is developed to be an accessible treatment—not dependant on expensive therapies.

While MEAI is a novel molecule, there are thousands of people who have used it recreationally in the past decade, and their personal testimonies indicate efficacy in humans.

Although this data is anecdotal only, and efficacy needs to be shown in clinical trials, management views this as a very positive indication.

Not many players in the pharma or psychedelics fields are working on new solutions to alcoholism:

Less than 2% of the active and completed psychedelic clinical trials are related to alcohol.

Only 5% of the psychedelic companies are working on alcohol use disorder.

19 patent families, 31 patents granted.

Patent jurisdictions include US, Europe, China and India.

Discovery programs expected to yield more patents in the near future.

Clinical trials expected to start in 2025.

Clinical trials will be conducted in Yale, John's Hopkins and Israel.

Development of alcohol substitute program.